Abbott offers the only systems that are FDA-approved to stimulate the dorsal root ganglion (DRG), an effective therapy that provides precise relief for patients suffering from causalgia or CRPS of the lower limbs.\(^1,2\)

The Proclaim™ DRG neurostimulation system provides clinically superior\(^2\) therapy on a platform designed for patients’ convenience.

The intense focal pain associated with causalgia and CRPS of the lower limbs, can often be attributed to nerve damage following an injury or surgical procedure. Examples of these conditions in the groin, hip, knee, ankle or foot leading to chronic pain may include the following:

- A suspected ilioinguinal or genitofemoral nerve injury following a hernia repair or vasectomy
- Abdominal surgery
- Total joint arthroplasties
- Limb amputation
- A surgery or traumatic injury of the hip, knee, ankle or foot

**ADVANCED NEUROSTIMULATION TECHNOLOGIES**

The Proclaim DRG neurostimulation system comes on a premium platform that includes Invisible Therapy\(^\text{TM}\), a system offering discreet and patient-friendly Bluetooth\(^\circledR\) wireless technology and Apple\(^\text{‡}\) mobile digital programming. A range of
other features enhance patient convenience, so they can focus on their lives and not on
pain.

LONGER BATTERY LIFE
The Proclaim DRG neurostimulation system offers a battery life of approximately 6.5
years at nominal settings\(^3\) potentially increasing the time between battery replacements
and reducing the number of procedures and replacement devices.

UPGRADABILITY
Upgradable technology—only from Abbott—allows patients to benefit from
advancements without surgery. As new technologies are approved, patients can receive
software upgrades, easily and painlessly.

CONVENIENT PROGRAMMING
The Proclaim DRG neurostimulation system lets patients and clinicians use wireless
programming with convenient and familiar technology. Patients can use the
Apple\(^\text{e}\) iPod\(^\text{e}\) controller to:

- ▪ Turn stimulation on and off
- ▪ Adjust stimulation settings
- ▪ Cycle through programs
- ▪ Assess IPG battery longevity

Clinicians can use the clinician programmer, featuring an Apple\(^\text{e}\) iPad mini\(^\text{e}\) mobile
digital device and downloadable programming app, to set programming parameters.

MR CONDITIONAL
The Proclaim DRG neurostimulation system is MR Conditional, allowing scans of the
head and extremities within approved MRI parameters.

DRG STIMULATION: A CLINICALLY PROVEN THERAPY
DRG stimulation’s effectiveness has been proven in the ACCURATE study, the
largest\(^2\) randomized clinical trial that compares traditional tonic SCS with DRG
stimulation, to manage causalgia and CRPS in the lower limbs. It has been clinically
proven to:

- ▪ Provide superior pain relief over traditional tonic SCS from causalgia and CRPS\(^2\)
- ▪ Provide persistent pain relief to 86% of patients at 12 months\(^2\)
- ▪ Reduce pain on average of 81.4% at 12 months\(^2\)

See more clinical evidence.

ST. JUDE MEDICAL™ INVISIBLE TRIAL SYSTEM WITH DRG STIMULATION
The St. Jude Medical™ Invisible Trial System with DRG Stimulation is designed to
closely mimic a permanent implant and provides an intuitive way for you and your
patients to evaluate whether DRG stimulation is effective for them. Learn more about
the St. Jude Medical™ Invisible Trial System with DRG Stimulation.
THE CHOICE FOR BETTER OUTCOMES®
Deliver precise relief to your focal chronic pain patients with the Proclaim DRG neurostimulation system—the choice for achieving superior outcomes® and positive patient experience.
Read more about our approach to chronic pain management.
IPG Specifications
The Proclaim™ DRG IPG has the following physical specifications.

Table 3. IPG specifications

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Range</th>
<th>Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model</td>
<td>3664</td>
<td></td>
</tr>
<tr>
<td>Height</td>
<td>6.09 cm (2.40 in)</td>
<td></td>
</tr>
<tr>
<td>Length</td>
<td>4.95 cm (1.95 in)</td>
<td></td>
</tr>
<tr>
<td>Thickness</td>
<td>1.34 cm (0.53 in)</td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>52.0 g (1.8 oz)</td>
<td></td>
</tr>
<tr>
<td>Volume</td>
<td>32.0 cm³ (2.0 in³)</td>
<td></td>
</tr>
<tr>
<td>Power source</td>
<td>Carbon monofluoride/silver vanadium oxide cell</td>
<td></td>
</tr>
<tr>
<td>Connector strength</td>
<td>Exceeds EN 45502-1 requirements</td>
<td></td>
</tr>
<tr>
<td>Program storage capacity</td>
<td>15 programs with 1 stim set per lead</td>
<td></td>
</tr>
<tr>
<td>Upgradeable features</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>MRI status*</td>
<td>MR Conditional</td>
<td></td>
</tr>
</tbody>
</table>

* The port plug (Model 7108), which is included in the IPG kit, is an MR Conditional component.

Table 4. Operating parameters for the IPG

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Range</th>
<th>Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse width</td>
<td>40–1000 µs</td>
<td>10 µs (40–500 µs range)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 µs (500–1000 µs range)</td>
</tr>
<tr>
<td>Frequency</td>
<td>4–80 Hz</td>
<td>2 Hz</td>
</tr>
<tr>
<td>Amplitude</td>
<td>0–6.000 mA</td>
<td>0.025–0.400 mA</td>
</tr>
</tbody>
</table>

NOTE: The maximum current depends on the impedance, frequency, and pulse width settings.
REFERENCES

*When compared to traditional tonic spinal cord stimulation based on outcomes from the ACCURATE IDE study.
**Based on new technologies available for DRG therapy.

1. Abbott. Data on File. SJM-PDRG-1017-0016